Mark of the Beast. The Beast Who Requires a ‘MARK.’ (7) The Infrared Vaccination QR Code SMART MARK.
Saudi Arabia Launches National Biotechnology Strategy To Become Global BioTech Hub by 2040
When Bill Gates says he has a new vaccine ‘patch’, he is actually talking about his human implantable quantum dot microneedle vaccine delivery system, and it will be powered by AI
Mark of the Beast. The Beast Who Requires a ‘MARK.’ (7) The Infrared Vaccination QR Code SMART MARK. It’s a vaccine technology that uses a tattoo-like mechanism which injects invisible (infrared) quantum dot nanoparticles under the skin, when Bill Gates speaks of it he calls it a ‘patch’. At Davos yesterday he told CNBC that the ‘patch’ is almost ready, just waiting for AI to catch up to make it all work. The quantum dots can be arranged in the form of an invisible ‘QR’ Code and injected ‘under the skin, which then can be scanned very quickly by infrared means.
Gates said this about the new era of vaccines that are coming soon. Gates said that “COVID vaccines need to have longer duration, more coverage, and we’re going to change. Instead of using needles, we’ll use a little patch.” That ‘patch’ is the human implantable quantum dot microneedle vaccine delivery system. Bill Gates, ‘GAVI’ and the World’s Vaccination Goals (start at 2:00 time stamp)
One World Government: Visa says palm biometric payments have promising future
Feb 27, 2024, 11:12 am EST | Masha Borak Biometric Update
Payments giant Visa showcased its pay-by-palm biometric payment technology at an event marking the transformation of its Singapore Innovation Center last week. During the event, visitors were invited to use the palm reader and link their signature to their payment card for a transaction. “The future of biometric payments is promising and is set to revolutionize the retail experience,” says Kunal Chatterjee, Head of Innovation at Visa Asia Pacific.
The technology is still relatively nascent and most likely won’t become mass market for a while, he adds. Various factors influence the acceptance of biometric payments, including regulation, technology and consumer acceptance which often depends on the market.
“However, the current pace of integration and acceptance of new technologies that we are seeing is very encouraging, and we expect to see biometric payments becoming more mainstream within the next decade,” Chatterjee told Singaporean tech news site Hardwarezone.
Visa first previewed its palm payment technology in 2015.
The year 2023 saw some progress in advancing palm-based payments. Amazon Web Service introduced its retail-focused palm payment system Amazon One in 200 locations across the U.S. The company is also hoping that more organizations will adopt its palm ID authentication system One Enterprise.
Over in China, WeChat Pay has partnered up with the Beijing Subway to allow palm-based payments on the high-speed Daxing International Airport Line. According to Chatterjee, some of the main benefits of biometric payments for Visa lie in offering more personalized, simpler and secure shopping. Visa showcased other payment and retail technologies in its Singapore Innovation Center, originally opened in 2016. These include augmented reality (AR) virtual shopping combined with predictive AI as well as business decision-making based on data.
Bioinformatics approach offers a step toward personalized immunotherapy for all
Story by Science X staff Medical Express
https://img-s-msn-com.akamaized.net/tenant/amp/entityid/AA1lm2x1.img
Most cancers are thought to evade the immune system. These cancers don’t carry very many mutations, and they aren’t infiltrated by cancer-fighting immune cells. Scientists call these cancers immunologically “cold.”
Now new research suggests such cancers aren’t as “cold” as once thought. Researchers from the La Jolla Institute for Immunology (LJI), UC San Diego Moores Cancer Center, and UC San Diego, have found that patients with “cold” tumors actually do make cancer-fighting T cells.
This discovery opens the door to developing vaccines or therapies to increase T cell numbers and treat many more types of cancer than currently thought possible.
“In virtually every patient we’ve looked at, with every kind of cancer we’ve analyzed, we can detect pre-existing natural immunity against their tumor’s immunogenic subset of mutations known as neoantigens,” says LJI Professor Stephen Schoenberger, Ph.D., who co-led the new study with LJI Professor Bjoern Peters, Ph.D. “Therefore, we think these patients may actually benefit from empowering this response through personalized immunotherapy.”
“Every cancer patient is different,” adds Peters. “But this research is an important step toward finding immune cell targets relevant for individual patient tumors.”
This new study was published in Science Translational Medicine and includes study co-first authors Aaron M. Miller, M.D., Ph.D., associate professor of medicine at UC San Diego School of Medicine and medical oncologist at UC San Diego Health, and Zeynep Koşaloğlu-Yalçın, Ph.D., LJI Instructor.
A new approach to finding cancer-fighting cells
T cells are always on the lookout for microbial invaders such as viruses and bacteria, which trigger responses from the innate and adaptive arms of the immune system. Cancers, being of “self” origin, don’t trigger the same innate immune response and are thought to thereby evade immune detection.
In some cases, especially with highly mutated tumors such as lung cancers and melanomas, the tumors look sufficiently different from normal, healthy cells to generate a T cell response against some of the mutations they carry.
Scientists have developed cancer therapies, such as immune checkpoint inhibitors, that take advantage of this natural T cell reactivity. Today, many patients with highly mutated types of cancer receive life-saving immunotherapies that harness the body’s own T cells to kill cancer cells.
Unfortunately, immunotherapies aren’t usually recommended for patients with immunologically “cold” tumors. Their tumors look especially similar to healthy tissue, which makes it hard for the immune system to detect the tumors and target them for destruction.
The new study started with a query from Miller and Ezra Cohen, MD, co-author of the study and medical oncologist at UC San Diego Health. Miller and Cohen wanted to take a closer look at T cell responses to “cold” tumors, and researchers with the LJI Center for Cancer Immunotherapy were eager to collaborate.
UC San Diego Moores Cancer Center scientists provided samples from 13 patients with eight different types of advanced solid tumors: microsatellite stable colorectal, pancreatic neuroendocrine, bile duct, ovarian, pancreatic ductal adenocarcinoma, appendiceal, head and neck squamous cell carcinoma, and renal cell malignancies. These cancers are known for being especially difficult to treat and generally don’t respond to checkpoint inhibitors alone.
The researchers first used genetic sequencing tools to identify mutations in these different cancers. Peters and his team then developed a bioinformatics approach to prioritize the mutations that might be “seen” as neoantigens by these T cells. This work showed where cancer cells might be vulnerable to T cell attack.
Next, the researchers went back to the patient samples. Did any patients actually produce T cells that could recognize these mutations?
The results were very encouraging. All 13 patients were already making T cells that could recognize mutations in their own cancers. These T cells were rare—but they were clearly there.
The researchers call this new approach “Identify, Predict, Validate,” or IPV. The researchers have gone on to use the IPV approach to detect T cells in more than 130 patients with 25 different types of cancer.
“The rapid and efficient identification of a patient’s tumor-specific neoantigens is crucial to the development of personalized immunotherapies, including neoantigen-specific cancer vaccinations,” says Miller. “The potential for a ‘cure from within’ is in every cancer patient we’ve looked at,” Schoenberger adds.
Developing new cancer vaccines
The researchers are now tackling a different problem: Patients with “cold” tumors just don’t make enough cancer-fighting T cells. “The patients who gave samples for this study were terminally ill,” says Schoenberger. “So you could argue that these T cells weren’t doing what we would like them to to do, which is to eradicate the tumor they recognize.”
The researchers continue to develop ways to increase the number and potency of neoantigen-specific T cells. For the study, researchers exposed T cells in the patient samples to the same mutations present in the original cancer cells. When T cells saw their targets, they naturally began producing effector cytokines and proliferating.
Schoenberger says personalized cancer vaccines can boost T cell numbers in a similar way. Schoenberger and his colleagues at UC San Diego Moores Cancer Center are currently conducting a clinical trial to test next-generation vaccines against different cancers. “The IPV approach helps us identify therapeutically ‘actionable’ mutations and improve the potency of these vaccines,” says Schoenberger.
“Our study is a wonderful example of institutional collaboration. It represents bench-to-bedside translational research that harnesses the strengths of each institution,” says Miller. “We are also encouraged that IPV can be used as a non-invasive tool for immune monitoring of enhanced T-cell responses in patients receiving effective immunotherapy treatments.”
Provided by La Jolla Institute for Immunology
Saudi Arabia and the WEF’s Fourth Industrial Revolution:
BEASTLY TECHNOLOGY OF THE COMING WORLD’S BEAST SYSTEM. The Fourth (4th) Kingdom Shall Be Different From All The Other Previous Kingdoms.
*******
In His Service,
Night Watchman
Paul Rolland
Night Watchman Ministries
Make Your (7) Decision for Christ NOW!!!!!!! Time is Up!!!!!!!
Jesus Christ’s Offer of Salvation:
The ABCs (7) of Salvation through Jesus Christ (the Lamb)
- (7) Admit/Acknowledge/Accept that you are sinner. Ask (7) God’s forgiveness and repent of your sins.
. . . “For all have sinned, and come short of the glory of God.” (Romans 3:23).
. . . “As it is written, There is none righteous, no, not one.” (Romans 3:10).
. . . “If we say that we have no sin, we deceive ourselves, and the truth is not in us.” (1 John 1:8).
B. Believe Jesus is Lord. Believe that (7) Jesus Christ is who He claimed to (7) be; that He was both fully God (7) and fully man and that we are (7) saved through His death, burial, and resurrection. (7) Put your trust in Him as your (7) only hope of salvation. Become a son (7) or daughter of God by receiving Christ. (7777777) 7×7
. . . “That whosoever believeth in him should not perish, but have eternal life. For God so loved the world, that he gave his only begotten Son, that whosoever believeth in him should not perish, but have everlasting life. For God sent not his son into the world to condemn the world; but that the world through him might be saved. (John 3:15-17). For whosoever shall call upon the name of the Lord shall be saved.” (Romans 10:13).
C. Call upon His name, Confess (7) with your heart and with your lips (7) that Jesus is your Lord and Savior.
. . . “That if thou shalt confess with thy mouth the Lord Jesus, and shalt believe in thine heart that God hath raised him from the dead, thou shalt be saved. For with the heart man believeth unto righteousness; and with the mouth confession is made unto salvation.” (Romans 10:9-10).
. . . “If we say that we have no sin, we deceive ourselves, and the truth is not in us. If we confess our sins, he is faithful and just to forgive us our sins, and to cleanse us from all unrighteousness. If we say that we have not sinned, we make him a liar, and his word is not in us.” (John 1:8-10).
. . . “And he is the propitiation for our sins: and not for ours only, but also for the sins of the whole world. (John 2:2).
. . . “In this was manifested the love of god toward us, because that God sent his only begotten Son into the world, that we might live through him. And we have seen and do testify that the Father sent the Son to be the Saviour of the world. Whosoever shall confess that Jesus is the Son of God, God dwelleth in him, and he in God.” (1 John 4:9, 14-15).
. . . “But God commendeth his love toward us, in that, while we were yet sinners, Christ died for us. Much more then, being now justified by his blood, we shall be saved from wrath through him. For if, when we were enemies, we were reconciled to God by the death of his Son, much more, being reconciled, we shall be saved by his life.” (Romans 5:8-10).
. . . “For the wages of sin is death; but the gift of God is eternal life through Jesus Christ our Lord.” (Romans 6:23).
. . . “Jesus saith unto them, I am the way, the truth, and the life, no man cometh unto the Father, but by me.” (John 14:6).
. . . “For I am not ashamed of the gospel of Christ: for it is the power of God unto salvation to everyone that believeth.” (Romans 1:16).
. . . “Neither is there salvation in any other: for there is none other name under heaven given among men, whereby we must be saved.” (Acts: 4:12).
. . . “Who will have all men to be saved, and to come unto the knowledge of the truth for there is one God, and one mediator between God and men, the man Christ Jesus.” (1 Timothy 2:4-6).
. . . “For God did not appoint us to suffer wrath but to receive salvation through our Lord Jesus Christ.” (1 Thessalonians 5:9).
. . . “But as many as received him, to them gave the power to become the sons of God, even to them that believe on his name.” (John 1:12).
True Church / Bride of Christ Spared from God’s Wrath:
Romans 5:8-10. “But God commendeth his love toward us, in that, while we were yet sinners, Christ died for us. Much more then, being now justified by his blood, we shall be saved from wrath through him. For if, when we were enemies, we were reconciled to God by the death of his Son, much more, being reconciled, we shall be saved by his life.”
Romans 12:19. Dearly beloved, avenge not yourselves, but rather give place unto wrath: for it is written, Vengeance is mine; I will repay, saith the Lord.
1 Thessalonians 1:10. And to wait for his Son from heaven, whom he raised from the dead, even Jesus, which delivered us from the wrath to come.
1 Thessalonians 5:9. For God hath not appointed us to wrath, but to obtain salvation by our Lord Jesus Christ,
Romans 8:35. Who shall separate us from the love of Christ? shall tribulation, or distress, or persecution, or famine, or nakedness, or peril, or sword?
Jeremiah 30:7. Alas! for that day is great, so that none is like it: it is even the time of Jacob’s trouble, but he shall be saved out of it.
Revelation 3:10 Because thou hast kept the word of my patience, I also will keep thee from the hour of temptation, which shall come upon all the world, to try them that dwell upon the earth.
Categories: 'Last' 'Latter' 'End of' Days, Cashless Transactions - Mark of the Beast, Christian Persecution Update, Deceptive Technology Update, Demonic Activity, Doctrines of Devils, Economic Collapse, Fig Tree Generation, Genetic Manipulation and Hybridization Update, Government Repression Control, Great Angel of Prophecy, GREAT WARNING!!!, Prophetic Timelines, Second Coming of Christ, Seven (7) Bowls, Seven (7) Seals, Six (6) Six (6) Six (6) - 666, The Final Generation, Those Left Behind, Tribulation Saints Beheaded, VISION 2030, White Throne Judgement